Neuss (ots) - In der kommenden Legislaturperiode - somit ab 2018 - soll das E-Health-Gesetz um einen zweiten ...
Bioreason Launches ClassPharmer(TM) Suite Lite for Lead Optimization and Predictive Tox
Santa Fe, New Mexico, November 29 (ots/PRNewswire) - Bioreason, Inc., announced today the release of ClassPharmer(TM) Suite Lite, a new edition of the company's software system to increase success in the hits-to-leads-to-clinic process within drug discovery. ClassPharmer(TM) Suite Lite is available from Bioreason's website for a free 30 day evaluation.
ClassPharmer(TM) Suite Lite includes all classification, modeling and structure-property-relationship extraction functionalities of the Desktop, Server and Batch editions and is capable of analyzing up to 2,000 compounds. The cost is 3,000 USD/EUR for a one-year license.
ClassPharmer(TM) Suite Lite makes Bioreason's patented technology affordable to drug discovery scientists involved in hit-to-lead, lead optimization and chemical toxicology analysis. Proven benefits include:
Increasing "true" hit recovery -- One customer using structure-guided consensus-scoring methods reported that ClassPharmer(TM) Suite increased the recovery of "true" hits by 200-300% in a virtual screen of 1,000 molecules.
Identifying novel leads and toxicophores -- One customer reported that ClassPharmer(TM) Suite Lite found a new structural motif they had not identified previously with any other in-house tools.
Reducing optimization time -- One customer reported that ClassPharmer(TM) Suite Lite had cut by 30% the time required for hit-to-lead and lead optimization.
With the new release, all 4 Editions of ClassPharmer(TM) Suite (Lite, Desktop, Server and Batch) offer new features that greatly improve the user's control over clustering and class modeling. Dr. Patricia Bacha, Product Manager for ClassPharmer(TM) Suite at Bioreason, explained, "There was a demand for our patented clustering algorithm to be more flexible. We added new clustering options such as using fuzzy atoms, created a post-processing step that organizes the classes into families, and allowed users to further refine the classification manually by merging classes."
Dr. Andrew DePristo, President and CEO of Bioreason, concluded, "The new version demonstrates our commitment to develop software to meet our customers' changing needs. Now, every Medicinal Chemist and Toxicologist can afford to have ClassPharmer(TM) Suite on the desktop!"
Bioreason, Inc., is headquartered in Santa Fe, NM with sales and support offices in Strasbourg (France) and is represented by CTC Laboratory Systems in Japan. Bioreason provides knowledge-based software, services, and collaborations that help increase the success of the hits-to-leads-to-clinic process in drug discovery. For information on the company, see www.bioreason.com.
Web site: http://www.bioreason.com
ots Originaltext: Bioreason, Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch
Andrew DePristo, President and CEO of Bioreason, Inc.,